Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 19, 2024

Tislelizumab vs Chemotherapy as Second-Line Therapy for European and North American Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

ESMO Open

 

Additional Info

ESMO Open
Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study
ESMO Open 2023 Dec 19;9(1)102202, J Ajani, F El Hajbi, D Cunningham, M Alsina, P Thuss-Patience, GV Scagliotti, M Van den Eynde, SB Kim, K Kato, L Shen, L Li, N Ding, J Shi, G Barnes, E Van Cutsem

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading